Alnylam Pharmaceuticals
ALNY
#434
Rank
C$73.83 B
Marketcap
C$558.87
Share price
-2.59%
Change (1 day)
55.29%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : C$1.80 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is C$1.80 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31C$1.85 B7.42%
2023-12-31C$1.73 B-3.36%
2022-12-31C$1.79 B40.91%
2021-12-31C$1.27 B91.31%
2020-12-31C$0.66 B67.47%
2019-12-31C$0.39 B871.01%
2018-12-31C$40.86 M8.35%
2017-12-31C$37.71 M-81.29%
2016-12-31C$0.20 B
2007-12-31C$6.74 M-36.62%
2006-12-31C$10.63 M23.55%
2005-12-31C$8.6 M-0.46%
2004-12-31C$8.64 M258.66%
2003-12-31C$2.41 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
C$0.48 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
C$3.73 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C$1.72 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C$0.54 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C$1.93 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
C$44.24 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$35.27 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
C$23.59 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel